Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
about
Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysisPharmacological treatments for acute hepatitis C infection: a network meta-analysisSafety and efficacy of daclatasvir in the management of patients with chronic hepatitis CLiver transplantation for viral hepatitis in 2015Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomesProgrammed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapyHepatitis C cirrhosis: New perspectives for diagnosis and treatmentTreatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos inHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyEmerging therapies for hepatitis CHepatitis C: New challenges in liver transplantationAntiviral therapies for chronic hepatitis C virus infection with cirrhosisTherapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisManagement of hepatitis C infection before and after liver transplantationHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsTreatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis CResults of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Hepatitis C treatment: where are we now?Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries.Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyOmbitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaEffectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosisFrontiers in the treatment of hepatitis C virus infection.Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world settingImprovement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Hepatitis C in Argentina: epidemiology and treatment.Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis.Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes.Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients
P2860
Q24186846-1DEDCD2B-0F1D-431C-B3BE-98B131DA59F1Q24186859-8245B8F2-D2E3-4EA3-B9EA-AA6F0DB8FCF7Q26745769-52FCB6EB-3E9A-4443-AFA9-F049E490FFD3Q26773224-5E947629-1818-4DE9-9CA6-38AA30D58286Q26777086-70C7D4F8-6EA2-4CE1-8362-2AE5A3F6D0E6Q26781481-60FBF248-88D1-4E89-9CCE-3B64315FAD8DQ26799924-B164386B-D57C-4034-BFA0-201D3CCC5D39Q26820811-27E30773-C1F9-44B6-88AC-4E09FD0594B3Q26853500-84C00E63-754C-45A9-BAC7-693A8F9A9B27Q26853642-9B8B3477-4AA3-4FCD-A851-021A0BA71660Q26999368-9326FCD5-CE9D-44C6-848F-26C3DF239E1FQ27022794-E8F5DB90-7552-451A-9E17-B480B0BC26A8Q28070260-66C06FBA-E69F-4778-95CF-B48164D0B1B2Q28081250-F854E7FD-DE5C-4CA3-BD8D-6C55CA950246Q28538891-717C6E24-74D1-491D-B8C6-29F9ABD88AD9Q28552691-43E345DB-EF76-4BA7-9807-58B0CF53F5CEQ30151392-335871AF-BE1A-4BAE-AB4A-4FF17669B0D4Q30361098-1383D125-ED46-4AA5-A87B-431A7E801ED9Q30378509-B3BA1757-D168-4F42-B3A9-FACBE7A11DFAQ30430083-F81A1CEC-AE85-4AFF-A7B6-7B0B67520A1CQ30614811-98B78778-D1C4-42C6-9C2A-38733FACBD79Q30620900-EE053C62-163D-4652-B97B-0C73B8B52944Q31051529-70F7A2D0-44F9-4859-87BC-87E3005D65E4Q31076943-FCB1C21C-9477-4ED4-A6FD-1151FB715D3AQ31170657-0EC20D69-E166-4897-AD5D-BCDA070F0A04Q33414392-885F867A-1E72-47F1-B8D0-CB7EF1218D52Q33414605-8A87EB40-930F-4CE9-8999-8EBBF6BBA480Q33424823-DC7528E1-E5C6-4F06-8D84-4675B60474B1Q33424963-BD1E2A69-9BEF-4CE6-832A-0FCE5CABF828Q33425278-A3C898A7-A623-4921-958C-232DC0B69B8BQ33571517-1CABF60C-8827-4D4A-BA31-E3F32E2191E0Q33576531-91C30695-F824-40D1-A069-39420D23FA40Q33646482-479A4344-9215-4013-989C-38E47801C133Q33703634-AEE0EA13-54C7-49D6-82D1-F860481C5074Q33706886-B140733E-04D4-451E-8466-4E08D9D15394Q33734454-C9F5E304-A6E4-4FDC-AC1D-F1DFF588C035Q33834742-03882282-613F-4FCF-9C8C-4E6D34C9B5F9Q33861095-32EC0698-CC55-4900-BC7B-3B158C6B69F0Q33915350-A1AE33B9-AABE-484A-9F53-41441DC9892DQ34057340-5DDA61A8-15E1-4B5B-9ED3-CC0AF0373481
P2860
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Triple therapy in treatment-ex ...... NRS CO20-CUPIC) - NCT01514890.
@en
Triple therapy in treatment-ex ...... French Early Access Programme
@nl
type
label
Triple therapy in treatment-ex ...... NRS CO20-CUPIC) - NCT01514890.
@en
Triple therapy in treatment-ex ...... French Early Access Programme
@nl
prefLabel
Triple therapy in treatment-ex ...... NRS CO20-CUPIC) - NCT01514890.
@en
Triple therapy in treatment-ex ...... French Early Access Programme
@nl
P2093
P50
P1476
Triple therapy in treatment-ex ...... NRS CO20-CUPIC) - NCT01514890.
@en
P2093
Albert Tran
Armand Abergel
CUPIC Study Group
Christophe Hézode
Cyrille Feray
Céline Dorival
Damien Lucidarme
Dominique Larrey
Fabien Zoulim
Ghassan Riachi
P304
P356
10.1016/J.JHEP.2013.04.035
P50
P577
2013-05-10T00:00:00Z